Good Guy in Bad Company: How STRNs Convert PP2A into an Oncoprotein

Kari J Kurppa; Jukka Westermarck

doi:10.1016/j.ccell.2020.06.011

Good Guy in Bad Company: How STRNs Convert PP2A into an Oncoprotein

Cancer Cell. 2020 Jul 13;38(1):20-22. doi: 10.1016/j.ccell.2020.06.011.

Authors

Kari J Kurppa¹, Jukka Westermarck²

Affiliations

¹ MediCity Research Laboratories, University of Turku, Turku, Finland; Institute of Biomedicine, University of Turku, Turku, Finland.
² Institute of Biomedicine, University of Turku, Turku, Finland; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland. Electronic address: jukka.westermarck@bioscience.fi.

PMID: 32663465
DOI: 10.1016/j.ccell.2020.06.011

Abstract

Certain Protein Phosphatase 2A (PP2A) complexes are human tumor suppressors. In contrast, a paper in this issue of Cancer Cell and two other recent studies demonstrate that PP2A-STRN3/4 complexes inactivate Hippo tumor suppressor pathway, resulting in YAP activation and tumorigenesis. Furthermore, this new oncogenic phosphatase mechanism may be druggable.

Publication types

Comment

MeSH terms

Autoantigens
Calmodulin-Binding Proteins
Hippo Signaling Pathway
Humans
Membrane Proteins
Nerve Tissue Proteins
Oncogene Proteins
Protein Phosphatase 2* / genetics
Protein Phosphatase 2* / metabolism
Protein Serine-Threonine Kinases
Stomach Neoplasms*

Substances

Autoantigens
Calmodulin-Binding Proteins
Membrane Proteins
Nerve Tissue Proteins
Oncogene Proteins
STRN protein, human
STRN3 protein, human
Protein Serine-Threonine Kinases
Protein Phosphatase 2